Definitive Contract 75N92022C00005
Award Date
11/5/21
Potential Completion Date
5/4/23
Potential Value
$15M
Federal Agency
National Heart Lung and Blood Institute
Awardee
ADL Diagnostics, Inc.
Ultimate Awardee
Not listed
NAICS Category
334516 - Analytical Laboratory Instrument Manufacturing
PSC Category
Q301 - Reference Laboratory Testing
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Woodinville, WA, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Health and Human Services' National Institutes of Health's National Heart, Lung and Blood Institute awarded a $22.57 million firm fixed price definitive contract to Flambeau Diagnostics LLC of Monona, Wisconsin. The contract is for the delivery of RADX TECH 2375 point-of-need, saliva-based COVID-19 testing platforms over a twenty-month period ending in March 2023. No subcontractors or set aside designations were indicated. The award supports the NIH's ongoing efforts to...
This definitive cost-plus-fixed-fee contract for $724,601.63 was awarded by the Department of Health and Human Services National Institutes of Health National Heart Lung and Blood Institute to Accel Diagnostics, LLC, doing business as ADX Diagnostic Lab, on November 19, 2018. The contract is associated with SBIR Topic 97, which involves research on early detection and monitoring of cardiac injury due to cardiotoxicity. With a completion date of November 18, 2021, this small business set-aside...
Sonic Healthcare USA Inc. was awarded a firm fixed price definitive contract valued at $20,550,149.95 by the National Institutes of Health National Heart Lung and Blood Institute to rapidly expand existing framework for deploying large-scale COVID-19 RT-PCR testing platforms and distributing testing capacities under the Rapid Acceleration of Diagnostics program. The work will be performed in Austin, Texas over a one year period ending in August 2021. This contract was awarded non-competitively...
The U.S. Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Heart Lung and Blood Institute awarded Ellume USA LLC, a foreign-owned, self-certified small disadvantaged business, a $26,900,000 firm-fixed-price contract for the development of a point-of-care COVID-19 antigen test for the direct detection of the SARS-CoV-2 virus. This contract, part of the RADX-TECH program, has a completion date of March 29, 2023 and does not have a set-aside designation....
The Department of Health and Human Services (HHS) National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $61,150.00 firm fixed price purchase order to Adaptive Biotechnologies Corporation, doing business as Adaptive, for SARS-COV-2 immunosequencing testing services. The contract has a performance period through September 30, 2024 and was awarded on May 7, 2024. Adaptive has previously provided specialized testing and genomic sequencing services to HHS,...
Adaptive Biotechnologies Corporation has been awarded a firm fixed price purchase order valued at thirteen thousand two hundred dollars from the Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases. Under this contract, Adaptive will provide laboratory testing, adaptive immunosequencing, and DNA extraction services in support of unspecified NIH research programs. Performance will take place in Seattle, Washington through...
This is a $24,860,014.00 firm-fixed-price contract awarded by the National Heart, Lung, and Blood Institute (NHLBI), a civilian agency, to Mesa Biotech Inc. for the development of an easy-to-use, low-cost molecular-based SARS-CoV-2 test. The contract is part of the Rapid Acceleration of Diagnostics (RADx) program, which aims to accelerate the development, validation, and commercialization of innovative COVID-19 testing technologies. The contract has a performance period ending on May 4, 2024,...
The National Institutes of Health awarded a $50.7 million firm fixed price modification to MicroGEM US Inc. under the RADX Tech Program. The modification extends an existing contract to maintain MicroGEM's production of 160,000 saliva-based, high-performing RT-PCR point-of-care cartridges and 1,000 portable devices per day for COVID-19 testing. The 25-minute tests and devices are non-invasive and portable. Funding comes from the Department of Health and Human Services National Institutes of...
Minute Molecular Diagnostics, Inc. was awarded a definitive, firm fixed price contract valued at seventeen million, five hundred ninety thousand dollars by the Department of Health and Human Services' National Institutes of Health National Heart, Lung and Blood Institute. The contract is for the RADX TECH PROJECT 2200 to develop a high-throughput, fast-turnaround, field-deployable COVID-19 molecular diagnostic system. Work will be performed in Evanston, Illinois with a period of performance...
The Broad Institute, Inc., doing business as the Broad Institute of MIT and Harvard, has been awarded a definitive contract valued at $25.7 million by the National Institutes of Health's National Heart, Lung and Blood Institute to scale the Broad Institute's reverse transcription polymerase chain reaction (RT-PCR) process to support testing of over 100,000 samples per day. This contract is part of the Rapid Acceleration of Diagnostics (RADx) Advanced Technology Platforms program, which aims to...